PDS BIOTECHNOLOGY CORP

PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium

24 Feb 2022 07:10:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer

15 Feb 2022 05:00:04 By Nasdaq GlobeNewswire

PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer

02 Feb 2022 05:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine

27 Jan 2022 05:00:02 By Nasdaq GlobeNewswire

PDS Biotechnology to Present at B. Riley Securities Virtual Oncology Conference

18 Jan 2022 05:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Presentation of PDS0101 Data at the 2022 Multidisciplinary Head and Neck Cancers Symposium

12 Jan 2022 05:00:01 By Nasdaq GlobeNewswire

PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy

10 Jan 2022 04:00:01 By Nasdaq GlobeNewswire

PDS Biotechnology to Present at H.C. Wainwright Bioconnect Virtual Conference

05 Jan 2022 05:00:02 By Nasdaq GlobeNewswire

PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

23 Dec 2021 13:00:00 By Nasdaq GlobeNewswire

PDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination

06 Dec 2021 05:30:00 By Nasdaq GlobeNewswire